Baxter International Inc. BAX
26.29 USD -0.14 (-0.51%)
Nov 11, 2026, 11:53 AM EST
25.98 Day range 26.45
15.80 52-week range 28.35
- YTD
- +37.55%
- 1 year
- +44.03%
News
benzinga.com Barclays Maintains Underweight on Baxter International, Raises Price Target to $23 Barclays analyst Christopher Pasquale maintains Baxter International (NYSE:BAX) with a Underweight and raises the price target from $20 to $23.
benzinga.com JP Morgan Maintains Neutral on Baxter International, Lowers Price Target to $25 JP Morgan analyst Robbie Marcus maintains Baxter International (NYSE:BAX) with a Neutral and lowers the price target from $26 to $25.
benzinga.com Wells Fargo Maintains Equal-Weight on Baxter International, Raises Price Target to $25 Wells Fargo analyst Larry Biegelsen maintains Baxter International (NYSE:BAX) with a Equal-Weight and raises the price target from $23 to $25.
benzinga.com Why Is Baxter Stock Trading Lower on Thursday? Baxter tops Q3 consensus with 58 cents EPS and $2.976 billion in sales, lifting fiscal 2026 profit and revenue guidance above Wall Street forecasts.
benzinga.com Baxter Intl Q3 2026 Earnings Call Transcript Baxter Intl (NYSE:BAX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Baxter International Raises FY2026 Adj EPS Guidance from $1.95-$2.15 to $2.05-$2.15 vs $2.05 Est; Raises FY2026 Sales Guidance from $11.581B-$11.694B to $11.694B-$11.806B vs $11.619B Est Baxter International (NYSE:BAX) raises FY2026 Adj EPS guidance from $1.95-$2.15 to $2.05-$2.15 vs $2.05 analyst estimate. Raises FY2026 sales outlook from $11.581 billion-$11.694 billion to $11.694…
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In September CVS, Steris and Baxter are oversold healthcare stocks with RSI readings near or below 30, potentially offering undervalued buying opportunities.
benzinga.com TD Cowen Maintains Hold on Baxter International, Raises Price Target to $29 TD Cowen analyst Joshua Jennings maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $24 to $29.- benzinga.com Wells Fargo Maintains Equal-Weight on Baxter International, Raises Price Target to $23 Wells Fargo analyst Larry Biegelsen maintains Baxter International (NYSE:BAX) with a Equal-Weight and raises the price target from $19 to $23.
benzinga.com Stifel Maintains Hold on Baxter International, Raises Price Target to $28 Stifel analyst Rick Wise maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $24 to $28.- benzinga.com Citigroup Upgrades Baxter International to Neutral, Raises Price Target to $28 Citigroup analyst Joanne Wuensch upgrades Baxter International (NYSE:BAX) from Sell to Neutral and raises the price target from $17 to $28.
benzinga.com Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress Baxter stock climbs after second-quarter earnings and revenue topped estimates as the company raised fiscal 2026 sales and profit guidance.- benzinga.com Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B-$11.356B to $11.581B-$11.694B vs $11.357B Est Baxter International (NYSE:BAX) raises FY2026 Adj EPS guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 analyst estimate. Raises FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.581…
benzinga.com Baxter Intl Q2 Adj. EPS $0.54 Beats $0.37 Estimate, Sales $2.960B Beat $2.795B Estimate Baxter Intl (NYSE:BAX) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.37 by 45.95 percent. This is a 8.47 percent decrease over earnings of $0.59 per…- benzinga.com UBS Maintains Neutral on Baxter International, Raises Price Target to $25 UBS analyst Patrick Wood maintains Baxter International (NYSE:BAX) with a Neutral and raises the price target from $19 to $25.
benzinga.com Stifel Maintains Hold on Baxter International, Raises Price Target to $24 Stifel analyst Rick Wise maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $19 to $24.
benzinga.com TD Cowen Maintains Hold on Baxter International, Raises Price Target to $24 TD Cowen analyst Joshua Jennings maintains Baxter International (NYSE:BAX) with a Hold and raises the price target from $20 to $24.- benzinga.com Goldman Sachs Maintains Neutral on Baxter International, Raises Price Target to $21 Goldman Sachs analyst David Roman maintains Baxter International (NYSE:BAX) with a Neutral and raises the price target from $19 to $21.
- benzinga.com Evercore ISI Group Maintains Outperform on Baxter International, Raises Price Target to $24 Evercore ISI Group analyst Vijay Kumar maintains Baxter International (NYSE:BAX) with a Outperform and raises the price target from $22 to $24.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com FDA Issues Early Alert Regarding Pressure Breathing Device Issue from Baxter https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-positive-pressure-breathing-device-issue-baxter
- benzinga.com Citigroup Downgrades Baxter International to Sell, Lowers Price Target to $17 Citigroup analyst Joanne Wuensch downgrades Baxter International (NYSE:BAX) from Neutral to Sell and lowers the price target from $19 to $17.
- benzinga.com Barclays Maintains Overweight on Baxter International, Raises Price Target to $27 Barclays analyst Matt Miksic maintains Baxter International (NYSE:BAX) with a Overweight and raises the price target from $25 to $27.
benzinga.com Baxter Profit Plunges 35% As Tariffs, Costs Bite Baxter tops earnings, but profit plunges 35% as tariffs and manufacturing costs rise; outlook for 2026 remains intact.- benzinga.com Baxter International Affirms FY2026 Adj EPS Guidance of $1.85-$2.05 vs $1.91 Est; Affirms FY2026 Sales Guidance of $11.244B-$11.356B vs $11.351B Est Baxter International (NYSE:BAX) affirms FY2026 Adj EPS guidance from $1.85-$2.05 to $1.85-$2.05 vs $1.91 analyst estimate. Affirms FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.244…
- benzinga.com Baxter International Affirms FY2026 Adj EPS Guidance of $1.85-$2.05 vs $1.91 Est Baxter International (NYSE:BAX) affirms FY2026 Adj EPS guidance from $1.85-$2.05 to $1.85-$2.05 vs $1.91 analyst estimate..
- benzinga.com Baxter Intl Q1 Adj. EPS $0.37 Beats $0.31 Estimate, Sales $2.701B Beat $2.616B Estimate Baxter Intl (NYSE:BAX) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.31 by 19.35 percent. This is a 40.32 percent decrease over earnings of $0.62 per…
benzinga.com Earnings Scheduled For April 30, 2026 
benzinga.com Alpha Buying: Following Conviction, Not the Crowd - benzinga.com Evercore ISI Group Maintains Outperform on Baxter International, Lowers Price Target to $22 Evercore ISI Group analyst Vijay Kumar maintains Baxter International (NYSE:BAX) with a Outperform and lowers the price target from $23 to $22.
benzinga.com EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks Oil prices have risen. Here's how Strait of Hormuz tensions could soon increase healthcare costs and make everyday medical supplies more expensive.
benzinga.com Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe Baxter warns of an EU-wide ifosfamide shortage until next year after manufacturing disruption, with supply quotas and treatment prioritization in place.- benzinga.com Baxter Notifying Healthcare Professionals About Ifosfamide-Containing Medicinal Products Shortage https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-holoxan-tronoxal-mitoxana-ifosfamide-500-mg-1-g-2-g-powder-solution-injection_en.pdf
- benzinga.com Baxter Intl Reaffirms FY2026 Adj EPS $1.85-$2.05 vs $2.25 Est; Sees Sales $11.244B-$11.356B vs $11.305B Est Baxter Intl (NYSE:BAX) is looking for FY2026 Adj EPS of $1.85-$2.05 vs $2.25 analyst estimate. sees sales of $11.244 billion-$11.356 billion vs $11.305 billion analyst estimate.
- benzinga.com Baxter International CFO Joel Grade Departs, Effective April 30; Anita Zielinski Named Interim CFO, Effective Immediately Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade. Mr. Grade is leaving the company…
benzinga.com Cisco Triggers Tech Selloff, VIX Spikes 16%: What's Moving Markets Thursday? A volatile Thursday rattled Wall Street, with technology and software stocks sliding across the board after a cautious margin outlook from Cisco Systems Inc.- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Earnings Scheduled For October 30, 2025 
benzinga.com S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon.
benzinga.com Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.
benzinga.com Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Earnings Scheduled For July 31, 2025
benzinga.com Earnings Scheduled For May 1, 2025 
benzinga.com DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - benzinga.com Earnings Scheduled For February 20, 2025
- benzinga.com Earnings Scheduled For February 13, 2025
benzinga.com Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.- benzinga.com Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
- benzinga.com AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday's Pre-Market Session